Next-generation STAT3 inhibitor TTI-109 reported topline healthy-volunteer results that confirm the prodrug design. The update highlighted improved tolerability and reductions in disease-relevant immune cell populations, supporting the clinical rationale for further development.
Next-generation STAT3 inhibitor TTI-109 reported topline healthy-volunteer results that confirm the prodrug design. The update highlighted improved tolerability and reductions in disease-relevant immune cell populations, supporting the clinical rationale for further development.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
mildly positive
Sentiment Score
0.25
